Gastroesophageal Reflux Disease Market Share

North American Market Forecast

North America industry is predicted to dominate the gastroesophageal reflux disease market with a majority revenue share of 35% by the end of 2037. The primary factor for the region’s proprietorship is the rising patient population in the region, which is highly prone to gastrointestinal problems. As per an article from NLM, published in October 2023, the rate of GERD prevalence in North America ranged between 18.1% and 27.8%. In addition, the estimated prevalence of heartburn at least once per week in this region ranged from 18% to 28%, with 25% of adults reporting heartburn daily (2023 NLM study). Furthermore, the rising awareness regarding drug therapies and early diagnosis, coupled with rigorous R&D cohorts are bringing new opportunities for global pioneers.

The U.S. market is augmenting with several growth drivers, including the increased cases of obesity and strong presence of pharma developers. For instance, till September 2024, approximately 20.0% of the adults residing across the nation were obese (CDC). The commercial distribution and development of therapeutics are further impelled by the supportive regulatory framework. This can be testified by the New Drug Application (NDA) clearance from the FDA for vonoprazan, attained by Phathom Pharmaceuticals in May 2023. This drug was indicated to treat erosive GERD.

APAC Market Analysis

The Asia Pacific gastroesophageal reflux disease market is estimated to grow at a notable pace and holds almost 24% share by the end of the discussed timeframe. The rising awareness about health and fitness among the people in the region and the increase in health spending is considered to be the primary factor for augmentation in this region. In addition, the expenditure on healthcare from foreign investors is increasing access to advanced care and R&D activities, which is favoring the new drug development. On this note, in December 2024, JW Pharmaceutical announced the commercial launch of a combination drug, Rabekhan Duo Tablet, treating GERD and gastric & duodenal ulcers.

With a large consumer base and generic medicine merchandise, India is emerging as an attractive landscape for greater revenue generation in the market. For instance, the OTC healthcare industry in this country is poised to attain USD 11.6 billion by 2026, owing to the increased disposable income and health awareness (International Journal of Pharmaceutical Sciences). The nation’s strong emphasis on the regional progress is also highlighted by the domestic innovations. In this regard, in June 2024, Akums Drugs & Pharmaceuticals Drugs Controller General of India (DCGI)-approved sodium alginate (IP 500mg) + potassium bicarbonate (IP 100mg) chewable tablet for GERD relief.